Altimmune

• NCT04972396

  Phase 1, Completed, 40 people, 22 Jul 2021

• Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial

  Fees or honoraria, 1 Oct 2026

• Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial

  Consulting or advice, Fees or honoraria, Board or leadership role, 29 Sept 2026

• Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes

  Fees or honoraria, Grants or research support, 18 Sept 2026

• Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis

  Consulting or advice, 4 Sept 2026

• Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging

  Grants or research support, 1 Sept 2026

• Incidence of Dementia in Older Adults Hospitalized With Acute Coronary Syndrome: Insights From KP-Brain-Heart Health Study

  Consulting or advice, Shares or equity, 28 Aug 2026

• Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial

  Consulting or advice, 28 Aug 2026

• Multi-Target HCC Blood Test Demonstrates Consistent Performance Across Subgroups of Patients with Chronic Liver Disease

  Consulting or advice, 27 Aug 2026

• Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception

  Consulting or advice, Fees or honoraria, 26 Aug 2026

• Alcohol, cardiometabolic risk factors, and cirrhosis: Ten-year risk estimates from a population-based Danish cohort

  Consulting or advice, Fees or honoraria, 24 Aug 2026

• The global cardiovascular-kidney-liver-metabolic burden from 1990 to 2023

  Consulting or advice, Fees or honoraria, 22 Aug 2026

• Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial

  Consulting or advice, 21 Aug 2026

• Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis

  Consulting or advice, Fees or honoraria, 18 Aug 2026

• Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis

  Consulting or advice, Fees or honoraria, Grants or research support, 7 Aug 2026

• Weight Loss Intervention Promoting an Adapted Mediterranean-Style Dietary Pattern: The DELISH Randomized Clinical Trial

  Fees or honoraria, 3 Aug 2026

• In vivo imaging of glutamate uncovers the neuroprotective effects of nicotinamide riboside on excitotoxicity in an Alzheimer's mouse model

  Consulting or advice, Fees or honoraria, 30 Jan 2026

• Hepatocyte mitochondrial NAD+ content is limiting for liver regeneration

  Consulting or advice, Fees or honoraria, 20 Nov 2025

• Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes

  Fees or honoraria, 3 Nov 2025

• The role of weight management in sleep disordered breathing

  Consulting or advice, Fees or honoraria, 16 Sept 2025

• Intensity, Duration, and Context Dependency of the Responses to Nutrient Surplus and Deprivation Signaling in the Heart: Insights Into the Complexities of Cardioprotection

  Consulting or advice, Fees or honoraria, 15 Sept 2025

Sources: pubmed.ncbi.nlm.nih.gov, europepmc.org

• Sleep-Related Outcomes in Patients with OSA Treated with Tirzepatide for Obesity or Overweight via Telehealth

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026

• Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025